Ayako Takizawa
YOU?
Author Swipe
View article: Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial
Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial Open
ClinicalTrials.gov NCT02999178.
View article: P16‐73: Prognostic significance of serum serological and radiological findings in idiopathic chronic fibrosing interstitial pneumonia
P16‐73: Prognostic significance of serum serological and radiological findings in idiopathic chronic fibrosing interstitial pneumonia Open
View article: Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial Open
In Japanese patients, nintedanib slowed ILD progression, evidenced by a reduction in the annual rate of decline in FVC vs placebo. The efficacy and safety of nintedanib in Japanese patients were consistent with the overall INBUILD populati…
View article: Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union
Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union Open
To understand assumptions about and approaches to interstitial lung disease (ILD), including those of the progressive phenotype (progressive fibrosing ILD), this multinational survey assessed physicians’ attitudes toward, knowledge of, and…
View article: Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease
Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease Open
The VESUTO study was funded by Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.
View article: The efficacy and safety of combined tiotropium and olodaterol via the Respimat<sup>&reg;</sup> inhaler in patients with COPD: results from the Japanese sub-population of the Tonado<sup>&reg;</sup> studies
The efficacy and safety of combined tiotropium and olodaterol via the Respimat<sup>®</sup> inhaler in patients with COPD: results from the Japanese sub-population of the Tonado<sup>®</sup> studies Open
Consistent with results from the overall population, T+O 5/5 μg was superior to each monotherapy for lung function and SGRQ in the Japanese sub-population of patients with COPD in Tonado(®).
View article: Efficacy and safety of the long-acting &beta;2-agonist olodaterol over 4&nbsp;weeks in Japanese patients with chronic obstructive pulmonary disease
Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease Open
ClinicalTrials.gov: NCT00824382.